Malin Corporation PLC traded at 3.84 this Tuesday June 28th, decreasing 0.01 or 0.26 percent since the previous trading session. Looking back, over the last four weeks, Malin Corporation PLC lost 11.72 percent. Over the last 12 months, its price fell by 48.80 percent. Looking ahead, we forecast Malin Corporation PLC to be priced at 3.70 by the end of this quarter and at 3.29 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eurofins Scientific SE 78.28 0.14 0.18% -19.61%
Lonza Group 511.60 -1.40 -0.27% -22.95%

Indexes Price Day Year
ISEQ 6435 -79.69 -1.22% -21.86%

Malin Corporation PLC
Malin Corporation plc is an Ireland-based global life sciences company. The Company's businesses include Altan, which is an injectable drug company; AN2H Discovery Limited, which focuses on designing novel small molecule therapeutics; Emba Medical Limited, which offers vascular embolization system; Emba Neuro Limited; Hatteras Venture Partners (HVP), which is a life sciences company; Immunocore, which is a biotechnology company; Jaan Health, which is a healthcare mobile technology company; Melinta Therapeutics, Inc.; Novan, Inc., which is a clinical stage company; Poseida Therapeutics, Inc., which is a human therapeutics company, and Viamet Pharmaceuticals, Inc., which is a drug discovery company. The Company operates through subsidiaries, and focuses on various therapeutic areas, including dermatology, anti-infective, pain, immunology, oncology, neurology, anatomy and other areas.

Financials